Jennifer Nessel, Assistant Editor

Although the levels of NDMA that was found through FDA testing are much lower than the levels that a few third-party investigators claimed, the report indicated that these levels exceed what the FDA considers acceptable for these medicines.

The largest ever trial of postoperative radiotherapy in prostate cancer shows men may be spared the procedure after surgery.

A new computer method could help reveal the origins of Crohn disease and improve early diagnosis and accuracy.

Stuck at work this Halloween? Gather your coworkers for some truly horrifying pharmacy pet peeves that are sure to keep you up at night.

Study suggests that men who use assisted reproduction techniques may benefit from early screening and long-term monitoring for prostate cancer.

Metabolic activity in the immune cells of patients with primary immunodeficiency was used as a biomarker due to cellular metabolism, which serves as a key regulator in immune cells.

The influenza A virus remains contagious in wet mucus from infected patients, even after being exposed to an ethanol-based disinfectant.

The 2019 National Association of Specialty Pharmacy (NASP) Annual Meeting and Expo began with a message of collaboration by the organization’s outgoing president, Carmine DeNardo, RPh, president and CEO of ReCept.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

Reform of pharmacy benefit management (PBM) practices has been an issue under much scrutiny due to a belief these entities play a significant role in exacerbating high drug costs.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

Trial finds that the addition of anti-HIV immune globulin to standard of care patients with influenza B had a significant virological benefit.

During the 2019 National Association of Specialty Pharmacy Annual Meeting and Expo, Ron Lanton III, Esq, reviewed the FDA Biosimilars Action Plan, its implications for the biosimilar marketplace, recent legislation set to influence the biosimilar pathway and drug accessibility, and the future of the biosimilar market.

Research explores why patients with mutated KRAS genes in tumor cells are sensitive to cetuximab.

Here are some ideas to help you celebrate the pharmacy profession all week long.

In "2019 State of Care: Oncology/ Hematology,” during the National Association of Specialty Pharmacy 2019 Annual Meeting and Expo in Washington, DC, Joseph Barone, PharmD, BCOP, examined current standards of care for acute myeloid leukemia (AML) and multiple myeloma (MM) and identified new agents approved over the past year.

After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.

Pending results of the California Practice Standards and Jurisprudence Exam (CPJE) have been invalidated for 1400 applicants that recently took the test, due to a cheating issue.

Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.

In the wake of California’s drug transparency law, an analysis by state health officials on pricing trends found that drug companies raised the whole acquisition cost dramatically for many drugs.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The new drug application for PF708 was submitted under the 505(b)(2) regulatory pathway with teriparatide injection as the reference drug.

Ixekizumab showed superiority versus guselkumab in the treatment of moderate to severe plaque psoriasis.

The PARP inhibitor received a Breakthrough Therapy Designation for metastatic castration-resistant prostate cancer based on data released from the GALAHAD study.

Two cell mutations have been linked to acute myeloid leukemia, but the reason for their cooperation has been unknown.

The funding is awarded to health departments representing 57 geographic areas to expand treatment and prevention efforts for HIV/AIDS.

The black-white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades.

The PREVENT trial revealed that secukinumab demonstrated both efficacy and a favorable safety profile for patients with non-radiographic axial spondyloarthritis (nr-axSpA).

A regimen of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab as monotherapy, led to an increased pathological complete response.

Improvements in overall survival and response rates found in patients with advanced hepatocellular carcinoma treated with first-line nivolumab.